Stocks and Investing Stocks and Investing
Thu, February 3, 2022

Etzer Darout Upgraded (ALNY) to Strong Buy and Held Target at $170 on, Feb 3rd, 2022


Published on 2024-10-27 19:33:05 - WOPRAI, Etzer Darout
  Print publication without navigation


Etzer Darout of Guggenheim, Upgraded "Alnylam Pharmaceuticals, Inc." (ALNY) to Strong Buy and Held Target at $170 on, Feb 3rd, 2022.

Etzer has made no other calls on ALNY in the last 4 months.



There are 10 other peers that have a rating on ALNY. Out of the 10 peers that are also analyzing ALNY, 1 agrees with Etzer's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Increased Target to $109 on, Friday, January 28th, 2022


These are the ratings of the 9 analyists that currently disagree with Etzer


  • Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $350 on, Thursday, January 20th, 2022
  • David Lebowitz of "Morgan Stanley" Maintained at Buy with Decreased Target to $215 on, Tuesday, January 18th, 2022
  • Edward Tenthoff of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $208 on, Monday, January 3rd, 2022
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $205 on, Monday, November 22nd, 2021
  • Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Held Target at $273 on, Monday, November 22nd, 2021
  • Luca Issi of "RBC Capital" Upgraded from Hold to Buy and Increased Target to $225 on, Monday, November 22nd, 2021
  • Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $200 on, Monday, November 1st, 2021
  • Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $200 on, Friday, October 29th, 2021
  • Esther Rajavelu of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $215 on, Monday, October 4th, 2021
Contributing Sources